How Lowering The Price of a Common Asthma Drug Made it Harde

To avoid Medicaid penalties, Glaxo and other drugmakers lowered prices. For popular asthma drug Flovent HFA, the tactic to replace it with a generic backfired.

Related Keywords

, Wsjhealth , Pharmaceuticals , Respiratory Allergy Treatments , Insurance , Non Life Insurance , Health Medical Insurance , Healthcare Life Sciences , Specialized Drugs Medications , Financial Services , Government Sponsored Health Insurance , Healthcare Support Services , Pharmacy Benefit Management , North America , United States , Prices , Corporate Industrial News , Markets Marketing , Asthma , Political General News , Respiratory Tract Diseases , Demographic Health , Health , Infant Child Teenage Health , Medical Conditions , Synd , Wsj Pro Com , Eli Lilly , Rally , Novo Nordisk , Novob Ko , Dk Novo B , Sanofi , San Fr , Fr San , Gsk , Gsk Ln , Uk Gsk , Unitedhealth Group , Unh , Link I2 Wp Wsj 0001459961 , Link I4 Wp Wsj 0001459961 , Link I5 Wp Wsj 0001459961 , Link I3 Wp Wsj 0001459961 , Corporate , Industrial News , Markets , Marketing , Political , General News , Infant , Child , Teenage Health , Respiratory , Allergy Treatments , Medical Insurance , Healthcare , Life Sciences , Specialized Drugs , Medications ,